earnings
confidence high
sentiment positive
materiality 0.85
Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B
VERTEX PHARMACEUTICALS INC / MA
2021-Q3 EPS reported
$6.03
revenue$5,501,839,000
- Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.
- Raised FY2021 product revenue guidance to $7.4-7.5B from prior $7.2-7.4B.
- TRIKAFTA/KAFTRIO net revenues $1.556B, up 62% YoY from $960M.
- Pipeline: VX-880 T1D positive data (1st patient); VX-147 Phase 2 results Q4; VX-548 data Q1 2022.
- CTX001 target enrollment achieved in TDT and SCD trials; regulatory submissions planned late 2022.